Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.29)
# 339
Out of 5,154 analysts
85
Total ratings
54.55%
Success rate
16.55%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $55 | $45.29 | +21.44% | 6 | Mar 4, 2026 | |
| BIIB Biogen | Maintains: Hold | $190 → $193 | $184.87 | +4.40% | 6 | Feb 9, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $60.41 | +52.29% | 5 | Feb 3, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $88 → $110 | $92.09 | +19.45% | 4 | Jan 5, 2026 | |
| SEPN Septerna | Initiates: Buy | $34 | $28.78 | +18.14% | 1 | Dec 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $83.49 | +38.94% | 6 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $35 → $56 | $42.82 | +30.78% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $432.83 | +47.86% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $95.94 | -3.06% | 12 | Oct 29, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $14.16 | +5.93% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $30.55 | +63.67% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $759.86 | +6.86% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $13.60 | -19.12% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $11.30 | +121.24% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $990.33 | +4.81% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $230.11 | -5.70% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $27.05 | +18.30% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $27.82 | +79.73% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.39 | +3,784.89% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $6.38 | +135.11% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $15.10 | +138.41% | 1 | Jul 31, 2024 |
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $44 → $55
Current: $45.29
Upside: +21.44%
Biogen
Feb 9, 2026
Maintains: Hold
Price Target: $190 → $193
Current: $184.87
Upside: +4.40%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $60.41
Upside: +52.29%
Protagonist Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $88 → $110
Current: $92.09
Upside: +19.45%
Septerna
Dec 15, 2025
Initiates: Buy
Price Target: $34
Current: $28.78
Upside: +18.14%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $83.49
Upside: +38.94%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $35 → $56
Current: $42.82
Upside: +30.78%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $432.83
Upside: +47.86%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $95.94
Upside: -3.06%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $14.16
Upside: +5.93%
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $30.55
Upside: +63.67%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $759.86
Upside: +6.86%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $13.60
Upside: -19.12%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $11.30
Upside: +121.24%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $990.33
Upside: +4.81%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $230.11
Upside: -5.70%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $27.05
Upside: +18.30%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $27.82
Upside: +79.73%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.39
Upside: +3,784.89%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $6.38
Upside: +135.11%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $15.10
Upside: +138.41%